---
title: "Replimune | 8-K: FY2026 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291143406.md"
datetime: "2026-06-29T12:13:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291143406.md)
  - [en](https://longbridge.com/en/news/291143406.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291143406.md)
generator: "portal-rs"
---

# Replimune | 8-K: FY2026 Revenue: USD 0

Revenue: As of FY2026, the actual value is USD 0.

EPS: As of FY2026, the actual value is USD -3.38, missing the estimate of USD -3.3643.

EBIT: As of FY2026, the actual value is USD -305.63 M.

### Financial Highlights (Fiscal Year Ended March 31, 2026 vs. 2025)

#### Cash Position

Cash, cash equivalents, and short-term investments for Replimune Group, Inc. were $268.9 million as of March 31, 2026, marking a decrease from $483.8 million as of March 31, 2025. This decline was attributed to cash burn from operating activities related to advancing the company’s clinical development plans.

#### Research and Development (R&D) Expenses

R&D expenses for the fiscal year ended March 31, 2026, were $221.2 million, an increase from $189.4 million for the fiscal year ended March 31, 2025. The year-over-year increase primarily stemmed from higher personnel-related costs as operations scaled for the commercial launch of RP1, along with increased consulting and facility-related costs. Stock-based compensation included in R&D expenses amounted to $16.7 million for the fiscal year ended March 31, 2026.

#### Selling, General and Administrative (S,G&A) Expenses

S,G&A expenses for the fiscal year ended March 31, 2026, were $98.7 million, an increase from $72.2 million for the fiscal year ended March 31, 2025. Stock-based compensation included in S,G&A expenses was $15.5 million for the fiscal year ended March 31, 2026.

#### Net Loss

The net loss for the fiscal year ended March 31, 2026, was -$313.9 million, compared to a net loss of -$247.3 million for the fiscal year ended March 31, 2025. Net loss per common share, basic and diluted, was -$3.38 for the fiscal year ended March 31, 2026, compared to -$3.07 for the prior fiscal year.

#### Other Financial Metrics

-   **Total Operating Expenses**: Total operating expenses were $319,919 thousand in 2026, an increase from $261,627 thousand in 2025.
-   **Loss from Operations**: The loss from operations was -$319,919 thousand in 2026, compared to -$261,627 thousand in 2025.
-   **Investment Income**: Investment income was $13,625 thousand in 2026, a decrease from $21,120 thousand in 2025.
-   **Working Capital**: Working capital was $220,891 thousand as of March 31, 2026, down from $433,518 thousand as of March 31, 2025.
-   **Total Assets**: Total assets were $332,388 thousand as of March 31, 2026, compared to $551,328 thousand as of March 31, 2025.
-   **Total Stockholders’ Equity**: Total stockholders’ equity was $166,160 thousand as of March 31, 2026, compared to $415,843 thousand as of March 31, 2025.

### Outlook/Guidance

Based on its current operating plan, Replimune Group, Inc. projects that its existing cash, cash equivalents, and short-term investments will fund operations into the first quarter of calendar year 2027. This projection includes resources for scaling up for the potential commercialization of RP1 in skin cancers, as well as for working capital and general corporate purposes. This guidance specifically excludes any potential revenue.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [16:20 ETRobbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action](https://longbridge.com/en/news/296649920.md)
- [Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL](https://longbridge.com/en/news/296198190.md)
- [Replimune grants CCO Michelle DiNapoli options for 150,000 shares at $15.58, plus 100,000 RSUs](https://longbridge.com/en/news/296394220.md)
- [FN: Record revenue and EPS growth in Q4 and FY26, with strong outlook for Q1 FY27](https://longbridge.com/en/news/296142824.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**